Combined phacoemulsification and microinvasive glaucoma surgery in comparison to phacoemulsification alone for open angle glaucoma.
Microinvasive glaucoma surgery (MIGS) combined with phacoemulsification is increasingly utilised in glaucoma management. To describe the postoperative outcomes of phacoemulsification alone compared to combined phacoemulsification and iStent (Glaukos, San Clemente, CA) or Hydrus (Ivantis, Irvine, CA) for open angle glaucoma. Retrospective single surgeon comparative case series in a private practice setting. A total of 297 eyes in 190 patients (M:F = 85:105) were included consecutively from March 2011 to June 2017 with the data analysed using linear mixed models. Main outcome measures were intraocular pressure (IOP) and number of medications. By 6 months, all groups showed a reduction in IOP, with the combined iStent group by 4.2 mm Hg and the combined Hydrus group by 4.5 mm Hg, and this trend was sustained with follow-up to two years. All groups also showed a reduction in number of medications, with the phacoemulsification alone cases by 0.3, the combined iStent group by 0.7 and the combined Hydrus group by 1.1 medications. Both the combined surgeries had sustained reduction of number of medications with follow-up to 2 years. Postoperative complications from MIGS device insertion were uncommon and all resolved by one month. The combination of phacoemulsification and a MIGS device in open angle glaucoma patients reduced the intraocular pressure and the number of medications by the first postoperative month and had longer-term effects at 2 years follow-up. If the device is inserted without intraoperative complication, the rate of significant short-term risks are low.